Expect Pfizer/BioNTech and Moderna Coronavirus Vaccine Data Readouts in November-December, U.S. Vaccine Program Head Says

The head of the U.S. government's Operation Warp Speed COVID-19 vaccine program, Moncef Slaoui, said he expects phase 3 clinical trial data for multiple coronavirus vaccines in the November-to-December timeframe. BNT162b2, the vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) and mRNA-1273 from Moderna (NASDAQ:MRNA) will be in the first round Slaoui said at a symposium conducted by the Johns Hopkins University and the University of Washington. Data on AstraZeneca's (NYSE:AZN) vaccine from studies in the U.K., Brazil, and South Africa could come in late October to November.